Since 2014, Staphylococcus aureus methicillin resistance has been rapidly increasing in New Caledonia and is associated with potential serious clinical repercussions. In the present study, we investigated the epidemiology of methicillin-resistant S. aureus (MRSA) in New Caledonia and the possible emergence of a particular clonal strain. An overview of the distribution of MRSA in New Caledonia in 2019 is presented. We collected and analysed 171 clinical MRSA isolates from New Caledonia medical laboratories during August and September 2019. Among this collection, 49 representative isolates were analyzed by the French National Reference Center for Staphylococci using the StaphyType DNA microarray, allowing genetic characterization of the isolates. Among the 1144 S. aureus isolated over the year 2019, 442 isolates (39%) were resistant to methicillin, and 62% of these isolates were resistant to fusidic acid (FA). During the inclusion period, FA resistance rate was similar (60%). Genetic characterization evidenced CC6 as the predominant clonal complex (70%) with 26 isolates (53%) identified as CC6-MRSA-[IV+fus] (PVL+). These findings demonstrated a low diversity of MRSA in New Caledonia, with the dominance of a clonal complex not reported previously. The frequent fusidic acid (FA) resistance in MRSA was associated with a high prevalence of fusC gene, suggesting that FA misuse contributed to driving the selection of this clone. Our findings suggest the recommendation to stop the topical use of FA to control the emergence of this severe MRSA clone and decrease the rate of MRSA in New Caledonia.

The increase in carbapenem-resistant Enterobacterales (CRE) is mostly driven by the spread of carbapenemase-producing (CP) strains. In New Caledonia, the majority of carbapenemases found are IMP-type carbapenemases that are difficult to detect on routine selective media. In this study, a culture-based method with ertapenem selection is proposed to distinguish non-CRE, non-CP-CRE, and CP-CRE from samples with very high bacterial loads. Firstly, assays were carried out with phenotypically well-characterized β-lactam-resistant Enterobacterales isolates. Then, this approach was applied to clinical and environmental samples. Presumptive CP-CRE isolates were finally identified, and the presence of a carbapenemase was assessed. In a collection of 27 phenotypically well-characterized β-lactam-resistant Enterobacterales, an ertapenem concentration of 0.5 µg·mL⁻¹ allowed distinguishing CRE from non-CRE. A concentration of 4 µg·mL⁻¹ allowed distinguishing CP-CRE from non-CP-CRE after nine hours of incubation. These methods allowed isolating 18 CP-CRE from hospital effluents, including the first detection of a KPC in New Caledonia. All these elements show that this cost-effective strategy to distinguish β-lactam-resistant Enterobacterales provides fast and reliable results. This could be applied in the Pacific islands or other resource-limited settings, where limited data are available.

Staphylococcus aureus is a major opportunistic pathogen responsible for a wide spectrum of human infections, including severe and difficult-to-treat cases. The emergence of multidrug-resistant strains limits the efficacy of conventional antibiotic therapies and poses a significant global public health challenge. In this context, the search for novel antibiotics has intensified, with increasing interest in marine resources, an ecosystem still largely underexplored. Marine bacteria produce a vast array of secondary metabolites with unique structures and potentially novel modes of antibacterial action. Several compounds isolated from marine bacterial strains have demonstrated promising activity against multidrug-resistant S. aureus, including antivirulence effects such as biofilm formation and Quorum-Sensing inhibition. This review explores the potential of marine bacteria as a source of new antibiotics against S. aureus, discusses both classical and advanced strategies for the discovery of bioactive molecules, and highlights the scientific and technological challenges involved in translating these findings into clinical applications.

To report a case of melioidosis in a domestic cat in New Caledonia, describing the diagnostic, microbiological and molecular findings. To evaluate the potential of a glanders serological test for assessing exposure to Burkholderia pseudomallei. A domestic cat presenting with respiratory symptoms underwent clinical and radiographic examination. Bacterial culture was performed on bronchoalveolar lavage fluid, and the strain was characterised using MALDI-TOF mass spectrometry and whole-genome sequencing. In silico multi-locus sequence typing (MLST) and phylogenetic analyses were also conducted. Serology was assessed using a commercial ELISA (GLANDA ELISA, IDVet), which was originally developed for diagnosing glanders. Burkholderia pseudomallei was isolated and sequenced, revealing ST2147, which has been previously identified in New Caledonia. Phylogenetic analysis confirmed clustering with strains from the Pacific region. The cat's serum tested strongly positive by ELISA, suggesting the potential of this test for assessing exposure to B. pseudomallei in cats and other animals. Screening of archived feline sera identified only one additional seropositive cat, suggesting low prevalence. This case supports the presence of multiple B. pseudomallei genotypes in New Caledonia and highlights the risk of melioidosis in cats. The commercial GLANDA ELISA shows promise as a tool for demonstrating animal exposure to B. pseudomallei, directing the need for culturing for confirmation of melioidosis. Enhanced awareness among veterinarians is essential for the early diagnosis and management of this disease in companion animals.